ARQT
Arcutis BiotherapeuticsCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Regulatory wins plus accelerating prescriptions drive above-consensus revenue and multiple expansion.
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -0.5.
What can break
Post-marketing safety signals
Momentum
18
Value
41
Sentiment
97
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $30.00 · Bull $45.00 · Bear $18.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-01-03 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $34.75
Why
Momentum18 · Δ7d +1.3
Value41 · Δ7d +0.1
Sentiment97 · Δ7d -0.5
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Sentiment · See AI snapshot
Momentum
18
34% active weight
Current posture
7d trendFlat
Δ7d
+1.3
Δ21d
+1.3
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
97
33% active weight
Current posture
7d trendFlat
Δ7d
-0.5
Δ21d
+8.7
Why this grade
Composite grade C. Momentum 17.9 / Value 41.1 / Sentiment 96.8
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$2.69B
Beta
1.71
Shares Out
122.49M
P/E (TTM) · Derived
-172.8
P/S (TTM)
11.64
P/FCF (TTM) · Derived
-58.05
Rev YoY
+121.7%
EPS YoY
+116.7%
Gross Margin
+90.0%
Op Margin
-12.0%
Net Debt
-$120.75M
Current Ratio
3.50
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology